Danske Bank’s Palvella Therapeutics PVLA Stock Holding History

Danske Bank’s Portfolio PVLA Stock Details PVLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-2	Closed	-$33	–	1682
2024 Q3	$33	Buy	+2	New	+$29	﹤0.01%	1490

Other funds holding PVLA

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Danske Bank's PVLA Position: Q4 2024 in Review

Danske Bank sold out of Palvella Therapeutics (PVLA) in Q4 2024, closing a stake of 2 shares — an estimated $33 sold.

Danske Bank first reported a position in PVLA in Q3 2024 and held it in 1 quarter. The position peaked at $33 in Q3 2024. 33 funds tracked by Wall St. Rank hold PVLA as of Q4 2024.

Danske Bank reported no remaining Palvella Therapeutics position as of Q4 2024 after selling out during the quarter.
Danske Bank sold 2 Palvella Therapeutics shares in Q4 2024, an estimated $33.
Danske Bank first reported a position in Palvella Therapeutics in Q3 2024 and held it in 1 quarter.
Danske Bank's Palvella Therapeutics position peaked at $33 in Q3 2024.
33 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q4 2024.

Based on Danske Bank's 13F filing for Q4 2024, filed 18 Mar 2026.